Literature DB >> 11406736

Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report.

G R Galluppi1, M C Rogge, L K Roskos, L J Lesko, M D Green, D W Feigal, C C Peck.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11406736     DOI： 10.1067/mcp.2001.115455

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  6 in total

Review 1.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 2.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

3.  Predicting brain concentrations of drug using positron emission tomography and venous input: modeling of arterial-venous concentration differences.

Authors:  Stina Syvänen; Gunnar Blomquist; Lieuwe Appel; Margareta Hammarlund-Udenaes; Bengt Långström; Mats Bergström
Journal:  Eur J Clin Pharmacol       Date:  2006-08-08       Impact factor: 2.953

4.  Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.

Authors:  Xin Zhang; Karen Schneck; Juliana Bue-Valleskey; Kwee Poo Yeo; Michael Heathman; Vikram Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

Review 5.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.

Authors:  Mats Bergström; Anders Grahnén; Bengt Långström
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

6.  Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.

Authors:  Xin Zhang; Laiyi Chua; Charles Ernest; William Macias; Terence Rooney; Lai San Tham
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.